An advisory council to Japan’s health minister approved on May 13 Amchepry, the world’s first iPS cell-based medicine for Parkinson’s disease, to be covered by public health insurance. A single treatment costs about 55.3 million yen before insurance. The drug, developed by Sumitomo Pharma Co., is in...
